Skip to main content

Mammographic Density

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Havah Therapeutics
Havah TherapeuticsAustralia - North Adelaide
2 programs
2
enobosarmPhase 11 trial
testosterone anastrozolePhase 1Small Molecule1 trial
Active Trials
NCT03264651Completed9Est. Mar 2018
NCT03314298Completed11Est. Apr 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Havah Therapeuticstestosterone anastrozole
Havah Therapeuticsenobosarm

Clinical Trials (2)

Total enrollment: 20 patients across 2 trials

NCT03314298Havah Therapeuticstestosterone anastrozole

A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole

Start: Aug 2017Est. completion: Apr 201811 patients
Phase 1Completed

Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density

Start: Feb 2017Est. completion: Mar 20189 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.